414 related articles for article (PubMed ID: 37181817)
1. Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2.
Mufamadi MS; Ngoepe MP; Nobela O; Maluleke N; Phorah B; Methula B; Maseko T; Masebe DI; Mufhandu HT; Katata-Seru LM
Biomed Res Int; 2023; 2023():4588659. PubMed ID: 37181817
[TBL] [Abstract][Full Text] [Related]
2. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
3. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Gong W; Parkkila S; Wu X; Aspatwar A
Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
[TBL] [Abstract][Full Text] [Related]
6. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
Noor R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
[TBL] [Abstract][Full Text] [Related]
7. A perspective on SARS-CoV-2 virus-like particles vaccines.
Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
[TBL] [Abstract][Full Text] [Related]
8. Vaccines against SARS-CoV-2 variants and future pandemics.
Park T; Hwang H; Moon S; Kang SG; Song S; Kim YH; Kim H; Ko EJ; Yoon SD; Kang SM; Hwang HS
Expert Rev Vaccines; 2022 Oct; 21(10):1363-1376. PubMed ID: 35924678
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.
Mei S; Fan Z; Liu X; Zhao F; Huang Y; Wei L; Hu Y; Xie Y; Wang L; Ai B; Liang C; Xu F; Guo F
Front Immunol; 2022; 13():911164. PubMed ID: 35935962
[TBL] [Abstract][Full Text] [Related]
10. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
11. Heterologous immunity induced by 1
Patel RS; Agrawal B
Front Immunol; 2022; 13():952229. PubMed ID: 36045689
[TBL] [Abstract][Full Text] [Related]
12. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants.
Li C; Guo Y; Fang Z; Zhang H; Zhang Y; Chen K
Front Immunol; 2022; 13():804945. PubMed ID: 35572594
[TBL] [Abstract][Full Text] [Related]
14. Nucleocapsid as a next-generation COVID-19 vaccine candidate.
Oronsky B; Larson C; Caroen S; Hedjran F; Sanchez A; Prokopenko E; Reid T
Int J Infect Dis; 2022 Sep; 122():529-530. PubMed ID: 35788417
[TBL] [Abstract][Full Text] [Related]
15. Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.
Simões RSQ; Rodríguez-Lázaro D
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206580
[TBL] [Abstract][Full Text] [Related]
16. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
[TBL] [Abstract][Full Text] [Related]
17. Development of SARS-CoV-2 animal vaccines using a stable and efficient NDV expression system.
He L; Zhong J; Li G; Lin Z; Zhao P; Yang C; Wang H; Zhang Y; Yang X; Wang Z
J Med Virol; 2023 Jan; 95(1):e28237. PubMed ID: 36258299
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants.
Abdi Ghavidel A; Rojhannezhad M; Kazemi B; Bandehpour M
Iran J Allergy Asthma Immunol; 2021 Dec; 20(6):647-671. PubMed ID: 34920649
[TBL] [Abstract][Full Text] [Related]
19. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Vaccines Against COVID-19 Variants: Beyond the Spike Protein.
Bonam SR; Hu H
Zoonoses (Burlingt); 2023; 3(1):. PubMed ID: 38031548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
